Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Post-transplant Cytomegalovirus (CMV) Infection/disease
Last updated May 10, 2024
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Metastatic castration-resistant prostate cancer (mCRPC) in adult patients (in combination with abiraterone and prednisone or prednisolone)
Last updated May 8, 2024
Paxlovid (nirmatrelvir/ritonavir)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Mild-to-moderate COVID-19, treatment
Last updated May 6, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Crohn's disease
Last updated April 26, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Ulcerative Colitis
Last updated April 26, 2024
Vyalev (foslevodopa foscarbidopa)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
Last updated April 26, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Ankylosing spondylitis
Last updated April 26, 2024
Status:
Concluded with an LOI
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Primary Hyperoxaluria Type 1
Last updated April 26, 2024
Suboxone (film) (buprenorphine and naloxone)
Status:
Concluded with an LOI
Manufacturer:
Indivior UK Limited
Indication:
Opioid Dependence
Last updated April 23, 2024
Status:
Negotiations were not pursued
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis
Last updated April 23, 2024